Clinical Trial

Molecular Imaging in Fabry Disease of the Heart

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated July 22, 2024 (before its estimated January 2, 2026 completion). Its status may not reflect the trial's current state.
Summary
Better methods for early detection of cardiac involvement in Fabry disease are needed to inform clinical management decisions that can help prevent or slow the progression of cardiac complications. In the Molecular Imaging of Inflammation in Fabry Disease of the Heart study, the investigators will test the use of 68Ga-DOTATATE PET/MRI for identifying myocardial inflammation in patients with Fabry disease.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06226987
Lead Sponsor University of Cambridge
Collaborators: Sanofi
Conditions Fabry Disease, Cardiac Variant
Enrollment 12 participants
Start Date 2024-01-02
Primary Completion 2026-01-02 (estimated)
Study Completion 2026-01-02 (estimated)
Updated on ClinicalTrials.gov 2024-07-22